 |
市场调查报告书
商品编码
2008061
福莱德瑞克运动失调症(FA) 市场：按药物类别、给药途径、分销管道和地区划分Friedreich's Ataxia Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
2026年福莱德瑞克运动失调症（FA）市场规模估计为7.935亿美元，预计到2033年将达到15.131亿美元。预计从2026年到2033年，其复合年增长率将达到10.5%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2025 | 2026年市场规模： | 7.935亿美元 |
| 历史数据时期： | 2020年至2024年 | 预测期： | 2026年至2033年 |
| 2026年至2033年预测期间的复合年增长率： | 10.50% | 2033年市场规模预测： | 15.131亿美元 |
共济失调是指一系列影响大脑协调和运动中枢（小脑）的神经退化性疾病。共济失调患者会出现吞嚥困难、言语障碍、平衡和协调能力下降。共济失调有多种类型，包括脊髓小脑变性、福莱德瑞克运动失调症（FA）、毛细血管扩张性共济失调、多系统萎缩症（MSA）和阵发性共济失调。福莱德瑞克运动失调症（FA）可发生于任何年龄，且是一种进行性疾病，这意味着症状会随着时间推移而加重。福莱德瑞克运动失调症（FA）是一种遗传性疾病，由缺陷基因引起，导致FA代代相传。除了常见的运动相关症状外，福莱德瑞克运动失调症（FA）患者还会出现肌肉僵硬和感觉丧失、全身肌肉无力以及心臟疾病（肥厚型心肌病病变）等症状。
市场动态
预计在预测期内，福莱德瑞克运动失调症（FA）市场成长的主要驱动力将是：福莱德瑞克运动失调症（FA）患者数量众多、技术进步以及市场主要企业越来越多地采用收购、合併和合作等非内部成长战略。
例如，根据 2022 年 2 月发表在同行评审开放获取科学期刊《神经科学前沿》上的一篇评论文章，截至 2021 年，弗里德赖希型共济失调的患病率估计为全球整体每 50,000 人中 1 人。
此外，2019 年 2 月，英国牛津大学和美国俄亥俄州一家大学医院的哈灵顿发现研究所宣布建立全球合作伙伴关係，以解决患有肌肉萎缩症萎缩症、囊肿纤维化和共济失调等罕见疾病的患者未被满足的需求。
本次调查的主要特点。
- 本报告对全球福莱德瑞克运动失调症（FA）市场进行了详细分析，以 2021 年为基准年，给出了预测期（2022-2030 年）的市场规模和復合年增长率。
- 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
- 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的重要见解。
- 本报告根据以下参数，介绍了全球福莱德瑞克运动失调症(FA) 市场的主要企业概况：公司概况、财务业绩、产品系列、市场地位、分销策略、主要发展、战略和未来计划。
- 透过利用本报告中提出的见解，企业行销负责人和经营团队将能够就未来的产品发布、产品升级、市场扩张和行销策略做出明智的决策。
- 本报告面向该产业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
- 透过对全球福莱德瑞克运动失调症（FA）市场进行分析时所使用的各种策略矩阵，相关人员将能够更轻鬆地做出决策。
目录
第一章：研究目标与前提条件
- 研究目标
- 前提
- 简称
第二章 市场范围
- 报告摘要
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第三章：市场动态、监管与趋势分析
- 市场动态
- 促进因素
- 阻碍因素
- 市场机会
- 影响分析
- 市场趋势
- 主要进展
- 产品核准
- 合作关係、併购
- 监理情势
- PEST分析
- 波特五力分析
- 流行病学
- 强大的管道分析
第四章：福莱德瑞克运动失调症（FA）市场：按药物类别划分，2026-2033年
- ACE抑制剂
- β受体阻断剂
- 利尿剂
- 对苯醌
- 其他（维生素E、免疫调节剂、骨骼肌鬆弛剂、抗癫痫药物等）
第五章：福莱德瑞克运动失调症（FA）市场：依给药途径划分，2026-2033年
- 口服
- 注射
第六章：福莱德瑞克运动失调症（FA）市场：依分销管道划分，2026-2033年
- 医院药房
- 零售药房
- 网路药房
第七章：福莱德瑞克运动失调症（FA）市场：按地区划分，2026-2033年
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
- 中东
- GCC
- 以色列
- 其他中东国家
- 非洲
- 北非
- 中非
- 南非
第八章 竞争情势
- 热图分析
- 市占率分析
- 公司简介
- Reata Pharmaceuticals, Inc.
- Retrotope Inc.
- Minoryx
- PTC Therapeutics
- Design Therapeutics, Inc.
- Larimar Therapeutics, Inc.
- Jupiter Neurosciences, Inc.
- Lexeo Therapeutics
- Zydus Lifesciences Ltd.
- Cipla Limited
- GlaxoSmithKline Plc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
第九章
- 参考
- 调查方法
- 关于本公司
简介目录
Product Code: CMI5034
Friedreich's Ataxia Market, is estimated to be valued at USD 793.5 Mn in 2026 and is expected to reach USD 1,513.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 793.5 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.50% | 2033 Value Projection: | USD 1,513.1 Mn |
Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be of several types such as spinocerebellar ataxia, Friedreich's ataxia, ataxia-telangiectasia, multiple system atrophy (MSA), episodic ataxia, and others. Friedreich's ataxia can develop at any age and is progressive in nature i.e. it worsens with time. Friedreich's ataxia (FA) is a genetic ataxia that is caused when a damaged gene which leads to FA is passed from one generation to the other. In addition to common movement related symptoms, people suffering from Friedreich's ataxia also experience symptoms such as stiffness and loss of sensation in muscles, weakness in the body, heart condition (hypertrophic cardiomyopathy), and others.
Market Dynamics
High burden of Friedreich's ataxia, rising technological advancements, and increasing adoption of inorganic growth strategies such as acquisitions, mergers, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global Friedreich's ataxia market over the forecast period.
For instance, according to a review article published by the Frontiers in Neuroscience journal, a peer-reviewed open access scientific journal, in February 2022, it was estimated that the prevalence of Friedreich ataxia was 1:50,000 individuals, around the globe as of 2021
Moreover, in February 2019, the University of Oxford, England and Harrington Discovery Institute at University Hospitals in Ohio, U.S. announced a global partnership to address unmet need of patients suffering from rare diseases such as muscular dystrophy, cystic fibrosis, ataxia, and others
Key features of the study
- This report provides an in-depth analysis of the global Friedreich's ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new Material launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Friedreich's ataxia market based on the following parameters - company overview, financial performance, Material portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Reata Pharmaceuticals, Inc., Retrotope Inc., Minoryx, PTC Therapeutics, Design Therapeutics, Inc., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Intas Pharmaceuticals Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future Material launches, type up-gradation, market expansion, and marketing tactics
- The global Friedreich's ataxia market report caters to various stakeholders in this industry including investors, suppliers, Material manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Friedreich's ataxia market
Market Segmentation
- By Drug Class
- ACE Inhibitors
- Beta Blockers
- Diuretics
- Para-Benzoquinone
- Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)
- By Route of Administration
- Oral
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Reata Pharmaceuticals, Inc.
- Retrotope Inc.
- Minoryx
- PTC Therapeutics
- Design Therapeutics, Inc.
- Larimar Therapeutics, Inc.
- Jupiter Neurosciences, Inc.
- Lexeo Therapeutics
- Zydus Lifesciences Ltd.
- Cipla Limited
- GlaxoSmithKline Plc.
- Aurobindo Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Friedreich's Ataxia Market, By Drug Class, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Beta Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Para-Benzoquinone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Others (Vitamin E, Immunomodulators, Skeletal Muscle Relaxants, and Anti-Epileptic Drugs, among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Friedreich's Ataxia Market, By Route of Administration, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Friedreich's Ataxia Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Friedreich's Ataxia Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Reata Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Retrotope Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Minoryx
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Design Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Larimar Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Jupiter Neurosciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lexeo Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Zydus Lifesciences Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Aurobindo Pharma Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Torrent Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
